Autologous blood or platelet-rich plasma injections
Platelet-rich plasma (PRP) and whole blood injections are treatments that have been utilized for a variety of healing applications in sports medicine and orthopedic medicine.
The page includes the Health Technology Clinical Committee (HTCC) decision only.
For current implementation status, see the relevant medical policy or billing guide for your plan or coverage.
Status: Decision completed
Decision summary
Autologous blood and platelet-rich plasma are not covered for any indications.
Documentation
| Type | Materials |
|---|---|
| Assessment (2023) | |
| Assessment (2016) |
Assessment timeline
- Draft key questions published: October 13, 2022
- Public comment period: October 13 to 27, 2022
- Final key questions published: November 29, 2022
- Draft report published: May 11, 2023
- Public comment period: May 11 to June 12, 2023
- Final report published: June 26, 2023
- HTCC public meeting: July 21, 2023
- Draft findings and decision published: July 27, 2023
- Public comment period: July 27 to August 10, 2023
- Final findings and decision published: November 20, 2023
All future dates are estimates and subject to change.